SOLO-1 phase III trial demonstrates Lynparza maintenance therapy cut the risk of disease progression or death by 70% in advanced BRCA-mutated ovarian cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Merck & Co., Inc. announced detailed results from the phase III SOLO-1 trial testing Lynparza (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.
NCI has emerged relatively unscathed in the president’s FY 2027 budget request that would slash $15.8 billion from HHS funding, cut NIH overall by about 10%, eliminate three NIH institutes and centers, and move the Institute for Environmental Health Sciences and its circa $1 billion budget out of NIH.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login